• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Calithera Biosciences Inc.

    3/14/23 4:15:58 PM ET
    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALA alert in real time by email
    15-12G 1 d481555d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR

    SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number: 001-36644

     

     

    Calithera Biosciences, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    343 Oyster Point Blvd., Suite 200

    South San Francisco, California 94080

    (650) 870-1000

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common Stock, $0.0001 par value

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: 13.

    Pursuant to the requirements of the Securities Exchange Act of 1934, Calithera Biosciences, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: March 14, 2023     By:   /S/ SUSAN M. MOLINEAUX, PH.D.
        Name:   Susan M. Molineaux, Ph.D.
        Title:   President and Chief Executive Officer

     

     

     

    Get the next $CALA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CALA

    DatePrice TargetRatingAnalyst
    1/31/2022$4.00Buy
    Ladenburg Thalmann
    1/20/2022$1.00 → $3.00Market Perform → Outperform
    SVB Leerink
    11/8/2021Buy → Neutral
    HC Wainwright & Co.
    11/5/2021Outperform → Market Perform
    William Blair
    More analyst ratings